{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=15", "query": { "intervention": "RAYOS", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 1199, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T06:18:40.905Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00809341", "title": "R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "High-dose cyclophosphamide", "type": "DRUG" }, { "name": "PET scan", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2009-01", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809341" }, { "nct_id": "NCT00141037", "title": "Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Diseases", "Kidney Transplantation", "Kidney Transplant", "Renal Transplantation", "Renal Transplant" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Trimethoprim and sulfamethoxazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 130, "start_date": "2004-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141037" }, { "nct_id": "NCT00774202", "title": "Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Immune Thrombocytopenic Purpura" ], "interventions": [ { "name": "Rituxan, Cyclophosphamide, Vincristine, Prednisone", "type": "DRUG" }, { "name": "Higher Dose of Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 17, "start_date": "2003-11", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2019-01-09", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774202" }, { "nct_id": "NCT05867329", "title": "Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis Acute" ], "interventions": [ { "name": "Cyclosporine Injection (IV)", "type": "DRUG" }, { "name": "Cyclosporine Oral Product", "type": "DRUG" }, { "name": "Upadacitinib Extended Release Oral Tablet", "type": "DRUG" }, { "name": "Intravenous Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone Oral Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Berinstein, Jeffrey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 700, "start_date": "2023-09-30", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867329" }, { "nct_id": "NCT04930094", "title": "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis (GCA)" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Secukinumab 150 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "50 Years to 100 Years" }, "enrollment_count": 354, "start_date": "2021-10-06", "completion_date": "2026-02-18", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 10, "location_summary": "Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04930094" }, { "nct_id": "NCT00675441", "title": "Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft-versus-Host Disease" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2008-04", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-12-11", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00675441" }, { "nct_id": "NCT06315309", "title": "Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GVHD,Acute", "Acute Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Disorders" ], "interventions": [ { "name": "ATG Combined with Tacrolimus and Mini Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 29, "start_date": "2025-04-15", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06315309" }, { "nct_id": "NCT07108387", "title": "Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Giant Cell Arteritis (GCA)" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Discontinue Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 78, "start_date": "2026-01-05", "completion_date": "2030-01-11", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07108387" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT00003343", "title": "Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "endocrine-modulating drug therapy", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "prinomastat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 525, "start_date": "1998-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-08-08", "last_synced_at": "2026-10-23T06:18:40.905Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003343" } ] }